Verici Dx plc (63V.F)
- Previous Close
0.0860 - Open
0.0805 - Bid --
- Ask --
- Day's Range
0.0805 - 0.0805 - 52 Week Range
0.0620 - 0.1920 - Volume
2 - Avg. Volume
0 - Market Cap (intraday)
20.502M - Beta (5Y Monthly) 1.48
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company also develops Protega, a peripheral blood-based test that aims to predict the risk of fibrosis and long-term graft failure. Verici Dx plc was incorporated in 2020 and is based in Penarth, the United Kingdom.
www.vericidx.com14
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 63V.F
Performance Overview: 63V.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 63V.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 63V.F
Valuation Measures
Market Cap
20.50M
Enterprise Value
16.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
774.41
Price/Book (mrq)
3.13
Enterprise Value/Revenue
852.01
Enterprise Value/EBITDA
-1.56
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.86%
Return on Equity (ttm)
-92.28%
Revenue (ttm)
19k
Net Income Avi to Common (ttm)
-11.21M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
5.25M
Total Debt/Equity (mrq)
9.28%
Levered Free Cash Flow (ttm)
-6.29M
Company Insights: 63V.F
63V.F does not have Company Insights